By Raffaele Pereno – PhD, MBA MILAN, Italy – At Bio Europe Spring 2025, Dr. Henrik Luessen, Chief Business Officer at Eleva Biologics, spotlighted the company’s lead therapeutic candidate, CPV-104, a recombinant human Factor H developed using Eleva’s proprietary moss-based manufacturing platform. A Unique Platform for Complex Biologics Eleva...
treatment News
New York, NY — Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance. The study, published in the October 30 online issue of Cell [DOI: 10.1016/j.cell.2024.10.006],...
By Raffaele Pereno – PhD, MBA LISBON, Portugal – During a meeting with Dr. Ross Macdonald, Chief Commercial Officer of StemSight, at BioEurope Spring, the discussion focused on a fundamental limitation in current treatments for limbal stem cell deficiency (LSCD) and how emerging cell therapy approaches may overcome it. LSCD...
Twenty-four parliamentarians across party lines have approached Union health and family welfare minister Mansukh Mandaviya, underlining the need for sustainable funding support for certain diseases under the National Policy for Rare Diseases 2021.
Minimal residual disease (MRD) assessment can be used to guide treatment discontinuation in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), according to phase 2 results published in the Journal of Clinical Oncology. The phase 2 CAPTIVATE trial (ClinicalTrials.gov Identifier: NCT02910583) was designed to test MRD-guided treatment discontinuation after first-line ibrutinib plus...
London, UK – The research, published in Science Translational Medicine, found that messenger RNA (mRNA) could be used to correct a rare liver genetic disease known as argininosuccinic aciduria in a mouse model of the disease. Argininosuccinic aciduria is an inherited metabolic disorder that affects how the body breaks down...
Atlanta, Ga. – Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced interim results from an ongoing, one-year longitudinal health-outcomes study in which patients reported significantly higher levels of treatment satisfaction after three infusions with TYSABRI® (natalizumab) when compared to multiple sclerosis (MS) therapies used previously. The...
ROCHESTER, Minn. — A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression. Results from a phase 3 clinical trial, published in the New England Journal...
MIAMI, FLORIDA – CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even for patients regarded as high risk due to comorbidities. That’s the conclusion of a five-year analysis of results from the U.S. Lymphoma CAR-T Cell Consortium, a group of 17 academic cancer...
Nashville, TN – Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome. Affecting 1 in 10,000 females at birth, and males even more rarely, Rett syndrome is...